Cargando…

Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia

BACKGROUND: Highly active antiretroviral therapy (HAART) has shown a dramatic change in controlling the burden of HIV/AIDS. However, the new challenge of HAART is to allow long-term sustainability. Toxicities, comorbidity, pregnancy, and treatment failure, among others, would result in frequent init...

Descripción completa

Detalles Bibliográficos
Autores principales: Birlie, Belay, Braekers, Roel, Awoke, Tadesse, Kasim, Adetayo, Shkedy, Ziv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488384/
https://www.ncbi.nlm.nih.gov/pubmed/28655306
http://dx.doi.org/10.1186/s12879-017-2533-3
_version_ 1783246642197037056
author Birlie, Belay
Braekers, Roel
Awoke, Tadesse
Kasim, Adetayo
Shkedy, Ziv
author_facet Birlie, Belay
Braekers, Roel
Awoke, Tadesse
Kasim, Adetayo
Shkedy, Ziv
author_sort Birlie, Belay
collection PubMed
description BACKGROUND: Highly active antiretroviral therapy (HAART) has shown a dramatic change in controlling the burden of HIV/AIDS. However, the new challenge of HAART is to allow long-term sustainability. Toxicities, comorbidity, pregnancy, and treatment failure, among others, would result in frequent initial HAART regimen change. The aim of this study was to evaluate the durability of first line antiretroviral therapy and to assess the causes of initial highly active antiretroviral therapeutic regimen changes among patients on HAART. METHODS: A Hospital based retrospective study was conducted from January 2007 to August 2013 at Jimma University Hospital, Southwest Ethiopia. Data on the prescribed ARV along with start date, switching date, and reason for change was collected. The primary outcome was defined as the time-to-treatment change. We adopted a multi-state survival modeling approach assuming each treatment regimen as state. We estimate the transition probability of patients to move from one regimen to another. RESULT: A total of 1284 ART naive patients were included in the study. Almost half of the patients (41.2%) changed their treatment during follow up for various reasons; 442 (34.4%) changed once and 86 (6.69%) changed more than once. Toxicity was the most common reason for treatment changes accounting for 48.94% of the changes, followed by comorbidity (New TB) 14.31%. The HAART combinations that were robust to treatment changes were tenofovir (TDF) + lamivudine (3TC)+ efavirenz (EFV), tenofovir + lamivudine (3TC) + nevirapine (NVP) and zidovudine (AZT) + lamivudine (3TC) + nevirapine (NVP) with 3.6%, 4.5% and 11% treatment changes, respectively. CONCLUSION: Moving away from drugs with poor safety profiles, such as stavudine(d4T), could reduce modification rates and this would improve regimen tolerability, while preserving future treatment options. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2533-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5488384
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54883842017-07-03 Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia Birlie, Belay Braekers, Roel Awoke, Tadesse Kasim, Adetayo Shkedy, Ziv BMC Infect Dis Research Article BACKGROUND: Highly active antiretroviral therapy (HAART) has shown a dramatic change in controlling the burden of HIV/AIDS. However, the new challenge of HAART is to allow long-term sustainability. Toxicities, comorbidity, pregnancy, and treatment failure, among others, would result in frequent initial HAART regimen change. The aim of this study was to evaluate the durability of first line antiretroviral therapy and to assess the causes of initial highly active antiretroviral therapeutic regimen changes among patients on HAART. METHODS: A Hospital based retrospective study was conducted from January 2007 to August 2013 at Jimma University Hospital, Southwest Ethiopia. Data on the prescribed ARV along with start date, switching date, and reason for change was collected. The primary outcome was defined as the time-to-treatment change. We adopted a multi-state survival modeling approach assuming each treatment regimen as state. We estimate the transition probability of patients to move from one regimen to another. RESULT: A total of 1284 ART naive patients were included in the study. Almost half of the patients (41.2%) changed their treatment during follow up for various reasons; 442 (34.4%) changed once and 86 (6.69%) changed more than once. Toxicity was the most common reason for treatment changes accounting for 48.94% of the changes, followed by comorbidity (New TB) 14.31%. The HAART combinations that were robust to treatment changes were tenofovir (TDF) + lamivudine (3TC)+ efavirenz (EFV), tenofovir + lamivudine (3TC) + nevirapine (NVP) and zidovudine (AZT) + lamivudine (3TC) + nevirapine (NVP) with 3.6%, 4.5% and 11% treatment changes, respectively. CONCLUSION: Moving away from drugs with poor safety profiles, such as stavudine(d4T), could reduce modification rates and this would improve regimen tolerability, while preserving future treatment options. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2533-3) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-27 /pmc/articles/PMC5488384/ /pubmed/28655306 http://dx.doi.org/10.1186/s12879-017-2533-3 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Birlie, Belay
Braekers, Roel
Awoke, Tadesse
Kasim, Adetayo
Shkedy, Ziv
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia
title Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia
title_full Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia
title_fullStr Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia
title_full_unstemmed Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia
title_short Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia
title_sort multi-state models for the analysis of time-to-treatment modification among hiv patients under highly active antiretroviral therapy in southwest ethiopia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488384/
https://www.ncbi.nlm.nih.gov/pubmed/28655306
http://dx.doi.org/10.1186/s12879-017-2533-3
work_keys_str_mv AT birliebelay multistatemodelsfortheanalysisoftimetotreatmentmodificationamonghivpatientsunderhighlyactiveantiretroviraltherapyinsouthwestethiopia
AT braekersroel multistatemodelsfortheanalysisoftimetotreatmentmodificationamonghivpatientsunderhighlyactiveantiretroviraltherapyinsouthwestethiopia
AT awoketadesse multistatemodelsfortheanalysisoftimetotreatmentmodificationamonghivpatientsunderhighlyactiveantiretroviraltherapyinsouthwestethiopia
AT kasimadetayo multistatemodelsfortheanalysisoftimetotreatmentmodificationamonghivpatientsunderhighlyactiveantiretroviraltherapyinsouthwestethiopia
AT shkedyziv multistatemodelsfortheanalysisoftimetotreatmentmodificationamonghivpatientsunderhighlyactiveantiretroviraltherapyinsouthwestethiopia